DrugPatentWatch Database Preview
QUZYTTIR Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
When do Quzyttir patents expire, and what generic alternatives are available?
Quzyttir is a drug marketed by JDP and is included in one NDA. There are five patents protecting this drug.
This drug has five patent family members in five countries.
The generic ingredient in QUZYTTIR is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and thirty-three suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.
US ANDA Litigation and Generic Entry Outlook for Quzyttir
A generic version of QUZYTTIR was approved as cetirizine hydrochloride by TEVA PHARMS on January 20th, 2020.
Summary for QUZYTTIR
| International Patents: | 5 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | QUZYTTIR at DailyMed |
Recent Clinical Trials for QUZYTTIR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| JDP Therapeutics, Inc. | Phase 2 |
| TerSera Therapeutics | Phase 2 |
Pharmacology for QUZYTTIR
| Drug Class | Histamine-1 Receptor Antagonist |
| Mechanism of Action | Histamine H1 Receptor Antagonists |
US Patents and Regulatory Information for QUZYTTIR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jdp | QUZYTTIR | cetirizine hydrochloride | SOLUTION;INTRAVENOUS | 211415-001 | Oct 4, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Jdp | QUZYTTIR | cetirizine hydrochloride | SOLUTION;INTRAVENOUS | 211415-001 | Oct 4, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Jdp | QUZYTTIR | cetirizine hydrochloride | SOLUTION;INTRAVENOUS | 211415-001 | Oct 4, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Jdp | QUZYTTIR | cetirizine hydrochloride | SOLUTION;INTRAVENOUS | 211415-001 | Oct 4, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Jdp | QUZYTTIR | cetirizine hydrochloride | SOLUTION;INTRAVENOUS | 211415-001 | Oct 4, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for QUZYTTIR
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2616703 | Start Trial |
| Canada | 2803987 | Start Trial |
| European Patent Office | 2477634 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2011003074 | Start Trial |
| Australia | 2010266103 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for QUZYTTIR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0663828 | C300085 | Netherlands | Start Trial | PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103 |
| 0058146 | 2001C/045 | Belgium | Start Trial | PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
